Consultant Gastroenterologist

  • Dr Miles Parkes is a consultant gastroenterologist at Addenbrooke's Hospital in Cambridge. He qualified from Oxford University (BA, 1st Class) and Imperial College, London (MBBS) and worked in London for three years before returning to Oxford for specialist training. He was appointed as a consultant gastroenterologist at Addenbrooke's in 2001, and as Director of Gastroenterology and Endoscopy in 2004. 

  • Dr Parkes holds a Bronze National Clinical Excellence Award in recognition of his services to the NHS.

  • Research interests include trials of new therapies in gastrointestinal disease and investigating the molecular genetic basis of Crohn's disease and ulcerative colitis. Dr Parkes heads an internationally renowned IBD research group and chairs the UK IBD genetics research consortium. This work has mainly been funded by the Wellcome Trust, the MRC and Crohn's and Colitis UK, and has resulted in a large number of publications and articles in high impact journals including Nature, Cell and Nature Genetics. He has also authored chapters for many textbooks, including the Oxford Textbook of Medicine which is widely regarded at the doctors bible, and is regularly invited to teach and lecture at home and at conferences in Europe, the USA and Australia.



  • BA 1st Class - University of Oxford

  • MRC Research Training Fellowship 1996-1999

  • National Clinical Excellence Award - Bronze 2010, 2015 and 2020

  • Invited lectures - British Society of Gastroenterology, American Gastroenterology Association, European Crohn's and Colitis Organization, United European Gastroenterology Week, Gastroenterology Society of Australia


​Selected Scientific Publications:  

  • Parkes M and IBD BioResource Investigators. IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn's and Colitis. Gut. 2019 Jul 3. pii: gutjnl-2019-318835. 

  • Castro-Dopico T, Dennison TW, Ferdinand JR, Mathews RJ, Fleming A, Clift D, Stewart BJ, Jing C, Strongili K, Labzin LI, Monk EJM, Saeb-Parsy K, Bryant CE, Clare S, Parkes M, Clatworthy MR. Anti-commensal IgG drives intestinal inflammation and type 17 immunity. Immunity. 2019 Apr 16;50(4):1099-1114

  • Biasci D, Lee JC, Noor NM, Pombal DR, Hou M, Lewis N, Ahmad T, Hart A, Parkes M, McKinney EF, Lyons PA, Smith KGC. A blood-based prognostic biomarker in IBD. Gut. 2019 Aug;68(8):1386-1395. 

  • Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, McDonald TJ, Lees CW, Cummings JRF, Parkes M, Mansfield JC, Irving PM, Barrett JC, McGovern D, Goodhand JR, Anderson CA, Ahmad T; PANTS Consortium. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastro  Hep. 2019 May;4(5):341-353. 

  • Kiely CJ, Clark A, Bhattacharyya J, Moran GW, Lee JC, Parkes M. Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with IBD. Dig Dis Sci. 2018 Apr;63(4):1011-1015. 

  • Lee JC, Biasci D, Roberts R… UK IBD Genetics Consortium, Traherne JA, Lyons PA, Parkes M, Smith KG. Genome-wide association study reveals distinct genetic contributions to prognosis and susceptibility in Crohn's disease. Nature Genetics.  2017 Feb;49(2):262-268

  • Luo Y, de Lange KM, Jostins L, Moutsianas L, … Wilson DC, Lee JC, Prescott NJ, Lees CW, Mathew CG, Parkes M, Barrett JC, Anderson CA. Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. Nature Genetics. 2017 Feb;49(2):186-192

  • de Lange KM, … Parkes M, Lees CW, Uhlig H, Hawkey C, Prescott NJ, Ahmad T, Mansfield JC, Anderson CA, Barrett JC. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nature Genetics. 2017 Feb;49(2):256-261.

  • Cesarini M, Collins GS, Rönnblom A, Santos A, Wang LM, Sjöberg D, Parkes M, Keshav S, Travis SP. Predicting the Individual Risk of Acute Severe Colitis at Diagnosis. J Crohns Colitis. 2016 Sep.

  • Ellinghaus D, Jostins L, Spain SL, Cortes A, …. McGovern DP, Karlsen TH, Barrett JC, Parkes M, Brown MA, Franke A. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nature Genetics. 2016 May;48(5):510-8

  • Cleynen I, Boucher G, Jostins L, .., Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016 9;387(10014):156-67.

  • Liu JZ, van Sommeren S, … Parkes M, Bk T, Daly MJ, Kubo M, Anderson CA, Weersma RK. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature Genetics. 2015 Sep;47(9):979-86.

  • Raine T, Liu JZ, Anderson CA, Parkes M*, Kaser A*. (* equal contribution) Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immune-mediated disease. Gut. 2015 Feb;64(2):250-9. doi: 10.1136/gutjnl-2013-306657. 

  • Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, Fleshner P, Stappenbeck TS, McGovern DP, Keshavarzian A, Mutlu EA, Sauk J, Gevers D, Xavier RJ, Wang D, Parkes M, Virgin HW. ­­­Disease-specific Alterations in the Enteric Virome in Inflammatory Bowel Disease. Cell 2015 Jan 29;160(3):447-60

  • Lee JC, Espéli M, Anderson CA, Linterman MA, Pocock JM, … Williams TN, Barton A, Vinuesa CG; UK IBD Genetics Consortium, Parkes M, Lyons PA, Smith KG.  Human SNP Links Differential Outcomes in Inflammatory and Infectious Disease to a FOXO3-Regulated Pathway. Cell. 2013;155:57-69.

  • Ellinghaus D, Zhang H, Zeissig S, … Rosenstiel P, Schreiber S, Parkes M*, Franke A*. Association Between Variants of PRDM1 and NDP52 and Crohn's Disease. Gastroenterology. 2013; Aug 145(2)

  • Parkes M, Cortes A, van Heel D, Brown M. Analysis Article: Genetic insights into common pathways and complex relationships among immune mediated diseases. Nature Reviews Genetics 2013. Sep;14(9):661-73

  • Jostins L, Ripke S, …Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH.   Host-microbe interactions shape genetic risk for inflammatory bowel disease. Nature, 2012 Nov 491(7422):119-24.

  • Cooke J, Zhang H, Greger L, Silva AL, Massey D, Dawson C, Metz A, Ibrahim A, Parkes M. Mucosal genome-wide methylation changes in inflammatory bowel disease. Inflamm Bowel Dis. 2012 Mar 14. 

  • Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr EJ, Bredin F, Rickman HM, Ratlamwala H, Hatton A, Rayner TF, Parkes M, Smith KG. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis.  J Clin Invest. 2011 Oct 3;121(10):4170-9 

  • Anderson CA, … Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011 Mar;43(3):246-52. 

  • Sharkey L, Bredin F, Nightingale A, Parkes M. The use of Ciclosporin A in Acute Severe Ulcerative Colitis: Long term outcomes, J Crohn’s and Colitis 2011 Apr;5(2):91-4. 

  • Lewis GJ, Massey DCO, … Lee JC, Berzuini C, Parkes M. Genetic association between NLRP3 variants and Crohn’s disease does not replicate in large UK panel. Inflamm Bowel Dis. 2011 Jun;17(6):1387-9 

  • Wellcome Trust Case Control Consortium. Craddock N, Hurles ME, …, Parkes M, Rahman N, Todd JA, Samani NJ, Donnelly P. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010 Apr 1;464(7289):713-20. 

  • Franke A, McGovern DP, Barrett JC, … Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M.  Genome-Wide Meta-Analysis Increases to 71 the Number of Confirmed Crohn’s Disease Susceptibility Loci. Nature Genetics. 2010;42(12):1118-25.

  • UK IBD Genetics Consortium, Barrett JC, Lee JC, …Mansfield JC, Satsangi J, Parkes M, Mathew CG and WTCCC2 Genome-wide association study of ulcerative colitis identifies three susceptibility loci, including HNF4A. Nature Genetics2009 Dec;41(12):1330-4. 

  • Anderson CA, Massey DC, Barrett JC, … Mathew C, Satsangi J, Parkes M.  Investigation of Crohn’s disease risk loci in Ulcerative Colitis further defines their molecular relationship. Gastroenterology 2009 Feb;136(2):523-9. 

  • Barrett JC, Hansoul S, Nicolae DL, Cho JH, … Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nature Genetics. 2008 Aug;40(8):955-62. 

  • Fisher SA, Tremelling M, … Wellcome Trust Case Control Consortium, Lobo A, Forbes A, Sanderson J, Jewell DP, Mansfield JC, Deloukas P, Mathew CG, Parkes M, Satsangi J. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nature Genetics 2008 Jun;40(6):710-2. 

  • Tremelling M, Berzuini C, Massey D, Bredin F, Price C, Dawson C, Bingham SA, Parkes M. Contribution of TNFSF15 gene variants to Crohn's disease susceptibility confirmed in UK population. Inflamm Bowel Dis. 2008 Jun;14(6):733-7. doi: 10.1002/ibd.20399.

  • Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA… Sanderson J, Jewell DP, Satsangi J, Mansfield JC; Wellcome Trust Case Control Consortium, Cardon L, Mathew CG. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease. Nature Genetics. 2007 Jul;39(7):830-2 

  • Wellcome Trust Case Control Consortium [Primary Investigators: Bentley D, …Parkes M, Pembrey M, Rahman N, Samani NJ, Stratton MR, Todd JA, Worthington J] Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.   Nature 2007; 447, 661-678 

  • Hugot JP, Zaccaria I, Cavanaugh J, Yang H, Vermeire S, Lappalainen M, Schreiber S, Annese V, Jewell DP, Fowler EV, Brant SR, Silverberg MS, Cho J, Rioux JD, Satsangi J, Parkes M for the IBD International Genetics Consortium.  Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol. 2007 Jun;102(6):1259-67 

  • Tremelling M, Cummings F, Fisher SA, Mansfield J, Gwilliam R, Keniry A, Nimmo ER, Drummond H, Onnie CM, Prescott NJ, Sanderson J, Bredin F, Berzuini C, Forbes A, Lewis CM, Cardon L, Deloukas P, Jewell D, Mathew CG, Parkes M, Satsangi J. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology. 2007 May;132(5):1657-64.

  • Tremelling M, Waller S, Bredin F and Parkes M. Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. Inflamm Bowel Dis. 2006 Mar;12(3):178-84

  • Waller S, Tremelling M, Bredin F, Godfrey L, Howson J and Parkes M. Evidence for association of OCTN genes and IBD5 with ulcerative colitis. Gut. 2006 Jun;55(6):809-14.

Recent Publications – reviews and chapters:

  • Parkes M and Raine T ‘Crohn’s Disease’ chapter in Oxford Textbook of Medicine 6th Edition, Eds John Firth, Christopher Conlon, Timothy M. Cox. Oxford University Press 2020. 

  • Noor NM, Verstockt B, Parkes M, Lee JC. Personalised medicine in Crohn's disease. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):80-92. doi: 10.1016/S2468-1253(19)30340-1.

  • Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27. 

  • Parkes M, Noor NM, Dowling F, Leung H, Bond S, Whitehead L, Upponi S, Kinnon P, Sandham AP, Lyons PA, McKinney EF, Smith KGC, Lee JC. PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial. BMJ Open. 2018 Dec 5;8(12):e026767. doi: 10.1136/bmjopen-2018-026767.

  • Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open. 2019 Feb 15;9(2):e023765. doi: 10.1136/bmjopen-2018-023765

  • Lamb CA et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. 

  • Weersma RK, Parkes M. Diverticular disease: picking pockets and population biobanks. Gut. 2019 May;68(5):769-770. doi: 10.1136/gutjnl-2019-318231.


07703 769695

©2020 by Parkes Medical Ltd.. Proudly created with